GE to invest $1 billion in cancer research

September 15, 2011

US industrial conglomerate General Electric said on Thursday that it would invest $1 billion in cancer research over the next five years.

GE chief executive Jeff Immelt and several venture capital partners launched the initiative, which will be aimed at improving for , the company said in a statement.

The investment will go toward research and development into technologies and solutions for cancer detection and treatment, beginning with breast cancer, GE said.

GE and its partners also announced a $100 million "global open innovation challenge" to provide grants to researchers who develop promising early-detection techniques.

The contest will focus on triple negative breast cancer, a particularly aggressive kind of breast cancer which is less responsive to standard treatments than other forms of the disease.

The winners will be announced in the first quarter of 2012 after selection by a jury that includes top cancer scientists as well as representatives of GE and its financial partners, the company said.

"We envision a day when cancer is no longer a ," Immelt said in the statement.

"When you add our cutting edge technologies to the innovative ideas of our new partners, it's a powerful formula for tackling cancer and helping doctors and researchers improve care."

GE's partners in the initiative include top venture-capital firm Kleiner Perkins Caufield & Byers as well as Venrock, Mohr Davidow and MPM Capital.

Explore further: Heart disease beats breast cancer as the biggest killer

Related Stories

Heart disease beats breast cancer as the biggest killer

June 19, 2011

Breast cancer accounts for almost a third of all cancer cases reported in women. However advances in the treatment for breast cancer, and early detection, have improved the chances of survival from the disease. New research ...

Recommended for you

Combination therapy can prevent cytostatic resistance

November 26, 2015

Researchers at Karolinska Institutet have found a new way of preventing resistance to cytostatics used in the treatment of cancers such as medulloblastoma, the most common form of malignant brain tumour in children. The promising ...

Forecasting the path of breast cancer in a patient

November 23, 2015

USC researchers have developed a mathematical model to forecast metastatic breast cancer survival rates using techniques usually reserved for weather prediction, financial forecasting and surfing the Web.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.